Prevalent and persistent new-onset autoantibodies in mild to severe COVID-19

Note: The DOI of the related paper will be provided upon publication.These datasets contain information on autoantibody and anti-SARS-CoV-2 IgG levels.In this study, 478 healthcare workers and 48 patients were followed prospectively over 5 visits from May 2020 to Sept 2021. SARS-CoV-2 serology and autoantibodies were assessed using planar and bead-based arrays. Detected epitopes were validated in blood and cerebrospinal fluid from two independent cohorts of Neuro-COVID patients (n=25) and pre-pandemic healthy controls (n=29).The datasets contain:SARS-CoV-2 serological profiles measured in all samples (above) using 3-plex bead arrays. The data is reported as raw and normalized MFI (AU) and compound serostatus.Proteome-wide autoantibody profiles measured in 12 sample pools using planar arrays. The data is reported as median fluorescent intensity, in raw and normalized arbitrary units (MFI [AU]), and reactivity classification.Targeted autoantibody profiles measured in 478 healthcare workers and 48 patients across 5 time points using 363-plex bead arrays. The data is reported as raw and normalized MFI (AU), fold change (FC) across infection, and new-onset classification.Peptide epitope mapping autoantibody profiles measured in a 142 healthcare workers and COVID-19 patients across 2 time points, and all Neuro-COVID patients (n=25) and pre-pandemic healthy controls (n=29), using 93-plex bead arrays. The data is reported as raw and normalized MFI (AU), and fold change (FC) across infection.Source data is provided with the paper.Access to this individual-level human data can be granted for non-commercial validation purposes and upon reasonable request to the provided contact. A reasonable request should contain the following:Name of PI and host organizationContact detailsThe scientific purpose of the data access requestCommitment to inform when the data has been used in a publicationCommitment not to host or share the data outside the requesting organizationStatement of non-commercial use of data

注意：相关论文的DOI将在发表后提供。本数据集包含关于自身抗体及抗SARS-CoV-2 IgG水平的详细信息。在本研究中，自2020年5月至2021年9月，对478名医疗工作者和48名患者进行了前瞻性追踪调查，共计5次访问。采用平面和珠基阵列对SARS-CoV-2血清学和自身抗体进行了检测。所检测到的表位在来自两个独立队列的神经COVID患者（n=25）和流感大流行前的健康对照者（n=29）的血液和脑脊液中得到了验证。数据集包含以下内容：使用3-plex珠基阵列对所有样本测量的SARS-CoV-2血清学特征，数据以原始和归一化MFI（AU）以及复合血清状态报告；使用平面阵列在12个样本池中测量的蛋白质组水平自身抗体特征，数据以中值荧光强度、原始和归一化任意单位（MFI [AU]）以及反应性分类报告；在5个时间点对478名医疗工作者和48名患者进行的363-plex珠基阵列测量的靶向自身抗体特征，数据以原始和归一化MFI（AU）、感染过程中的倍数变化（FC）以及新发分类报告；在142名医疗工作者和COVID-19患者、所有神经COVID患者（n=25）以及流感大流行前的健康对照者（n=29）中测量的肽表位映射自身抗体特征，数据以原始和归一化MFI（AU）以及感染过程中的倍数变化（FC）报告。源数据随论文一同提供。为非商业验证目的，并经合理请求，可提供个人层面的数据访问权限。合理的请求应包含以下内容：PI姓名及所属机构联系方式、数据访问的科学目的、承诺在出版物中使用数据时进行通知、承诺不在请求机构之外托管或分享数据、声明数据非商业用途。